TITLE

Hepatitis C Therapy: Is It Really Worth It?

AUTHOR(S)
Johanson, John F.; Johnson, David
PUB. DATE
May 1999
SOURCE
American Journal of Gastroenterology;May1999, Vol. 94 Issue 5, p1412
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents a study which compared the clinical and economic outcomes of interferon-alpha therapy in patients with chronic hepatitis C virus (HCV) infection. Use of a Markov type decision analysis model to simulate the natural history of HCV infection; Association of an increase in quality adjusted life years with inteferon treatment; Incremental cost-effectiveness of interferon-alpha treatment of HCV infection by age group.
ACCESSION #
16070943

 

Related Articles

  • Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Ali, Sajid; Ali, Ijaz; Azam, Sadiq; Ahmad, Bashir // Virology Journal;2011, Vol. 8 Issue 1, p193 

    Background: Hepatitis C Virus (HCV) genotypes frequency is important for the predication of response to therapy and duration of treatment. Despite variable response rates experienced in the case of Interferon (IFN) -based therapies, there was scarcity of data on HCV genotypes frequency in Khyber...

  • Genomics: Hepatitis C virus gets personal. Iadonato, Shawn P.; Katze, Michael G. // Nature;9/17/2009, Vol. 461 Issue 7262, p357 

    The article attempts to investigate on the effectiveness of human genetic variant in eliminating hepatitis C virus (HCV). According to the authors, there are about 1701 million people are suffering from the infections of hepatitis C virus in the U.S. and European countries and cites that there...

  • IFN Therapy for HCV Can Increase Glomerulopathies.  // Kidney;Nov/Dec99, Vol. 8 Issue 6, p241 

    Focuses on the pathogenesis of proteinuria during interferon (IFN) therapy in patients infected with the hepatitis C virus (HCV). Finding that glomerular deposition of immunoglobulin G or immunoglobulin A and complements in all patients using immunofluorescence; Need for physicians to carefully...

  • Adverse Cutaneous Reactions to Interferon Alfa-2b Plus Ribavirin Therapy in Patients with Chronic Hepatitis C Virus. Manjón-Haces, Joséantonio; Vázquez-López, Francisco; Gómez-Díez, Santiago; Hidalgo-García, Yolanda; Pérez-Alvarez, Ramón; Soler-Sánchez, Tomás; Pérez-Oliva, Narciso // Acta Dermato-Venereologica;Jun/Jul2001, Vol. 81 Issue 3, p223 

    Discusses adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus (HCV). Impact of interferon alfa-2b therapy on patients with HCV; Types of lesions present in patients; Reason provided regarding the need to produce a proper information...

  • Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Kobayashi, Makoto; Watanabe, Kazumasa; Ishigami, Masatoshi; Murase, Kenichi; Ito, Hiroshi; Ukai, Koji; Yano, Motoyoshi; Takagi, Kenji; Hattori, Masaki; Kakumu, Shinichi; Yoshioka, Kentaro // American Journal of Gastroenterology;Apr2002, Vol. 97 Issue 4, p988 

    OBJECTIVES:The interferon sensitivity-determining region (ISDR) in nonstructural region 5A (NS5A) of hepatitis C virus genotype 1b has been reported to correlate with response to interferon therapy and viral load. Recently the correlation between NS5A and response to interferon in genotype 2a...

  • Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. Furuta, Masahiko; Kaito, Masahiko; Gabazza, Esteban; Fujita, Naoki; Ishida, Satoshi; Tamaki, Shigenori; Ikeda, Ritsuko; Wakisawa, Shinya; Hayashi, Hisao; Watanabe, Shozo; Adachi, Yukihiko // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p60 

    Abstract: Many patients with porphyria cutanea tarda (PCT) have been reported to be hepatitis C virus (HCV) carriers, suggesting that HCV infection plays a role in the pathogenesis of this type of porphyria. In this study, we report a patient with chronic hepatitis C-associated PCT. Therapy with...

  • Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. Arase, Yasuji; Ikeda, Kenji; Tsubota, Akihito; Suzuki, Yoshiyuki; Saitoh, Satoshi; Kobayashi, Masahiro; Kobayashi, Mariko; Suzuki, Fumitaka; Akuta, Norio; Someya, Takashi; Kumada, Hiromitsu // Journal of Gastroenterology;2003, Vol. 38 Issue 2, p158 

    Background In patients with hepatitis C virus (HCV)genotype 1b and a high virus load, of more than 1 Meq/ ml by the DNA probe assay, the clearance of HCVRNA was achieved in only 10% with a 6-month interferon (IFN) course. We therefore assessed the efficacy of prolonged IFN therapy in patients...

  • Peginterferon lambda-1a decreased viral load more quickly, safely vs. alfa-2a in HCV. Taliercio, Adam // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p49 

    The article reports on a study which found a decrease in hepatitis C virus RNA and fewer side effects in noncirrhotic patients with chronic hepatitis C virus who received pegylated interferon lambda-la.

  • Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to... Zein, Nizar N.; Rakela, Jorge // Annals of Internal Medicine;10/15/96, Vol. 125 Issue 8, p634 

    Studies the geographic distribution and clinical significance of hepatitis C virus (HCV) genotypes in the United States. Examination of the influence of HCV genotypes on response to interferon therapy; Predominance of HCV genotypes 1a and 1b in patients with chronic hepatitis C; Absence of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics